New drug could extend lung transplant survival
NCT ID NCT06948097
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 40 times
Summary
This study tests a drug called fostamatinib in 30 adults who have received a lung transplant and developed donor-specific antibodies (DSA), which can lead to organ rejection. Participants take the drug or a placebo daily for 8 weeks while continuing standard care. The goal is to see if the drug is safe and helps prevent rejection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Inova Health System Foundation
Falls Church, Virginia, 22042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stanford University School of Medicine
Stanford, California, 94305, United States
-
University of Utah Health
Salt Lake City, Utah, 84132, United States
Conditions
Explore the condition pages connected to this study.